These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31526399)

  • 21. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
    Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
    Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.
    Citarella A; Linder M; Kieler H; Berglind IA; Sundström A; Wettermark B; Andersen M
    Eur J Clin Pharmacol; 2016 Mar; 72(3):349-57. PubMed ID: 26671240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year.
    Tran JN; Kao TC; Caglar T; Stockl KM; Spertus JA; Lew HC; Solow BK; Chan PS
    J Manag Care Spec Pharm; 2016 Aug; 22(8):901-8. PubMed ID: 27459652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey.
    Fan W; Philip S; Granowitz C; Toth PP; Wong ND
    J Clin Lipidol; 2019; 13(1):100-108. PubMed ID: 30594443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN.
    Stegman B; Shao M; Nicholls SJ; Elshazly M; Cho L; King P; Kapadia S; Tuzcu M; Nissen SE; Puri R
    Atherosclerosis; 2016 Nov; 254():78-84. PubMed ID: 27710808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease.
    Chamberlain AM; Cohen SS; Weston SA; Fox KM; Xiang P; Killian JM; Qian Y
    Am J Cardiol; 2019 Jun; 123(11):1739-1744. PubMed ID: 30948001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients.
    Lama S; Souraya D; Youssef F
    Int J Clin Pharm; 2017 Aug; 39(4):919-926. PubMed ID: 28523462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
    Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
    Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016.
    Romanelli RJ; Ito MK; Karalis DG; Huang HC; Iorga ŞR; Kam IW; Thompson S; Azar KMJ
    J Clin Lipidol; 2020; 14(3):305-314. PubMed ID: 32362513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.
    Anderson JL; Knowlton KU; May HT; Bair TL; Armstrong SO; Lappé DL; Muhlestein JB
    J Clin Lipidol; 2018; 12(4):1008-1018.e1. PubMed ID: 29703626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database.
    Sazonov V; Beetsch J; Phatak H; Wentworth C; Evans M
    Atherosclerosis; 2010 Jan; 208(1):210-6. PubMed ID: 19766999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guidelines impact cholesterol management.
    Yu S; Zolfaghari K; Rascati KL; Copeland LA; Godley PJ; McNeal C
    J Clin Lipidol; 2019; 13(3):432-442. PubMed ID: 30992244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article).
    Hyun MH; Jang JW; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Medicine (Baltimore); 2019 Dec; 98(51):e18510. PubMed ID: 31861037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disparities in lipid control and statin drug use among diabetics with noncoronary atherosclerotic vascular disease vs those with coronary artery disease.
    Thapa R; Sharma S; Jeevanantham V; Hu C; Myers T; Vacek JL; Dawn B; Gupta K
    J Clin Lipidol; 2015; 9(2):241-6. PubMed ID: 25911081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus.
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    J Diabetes Complications; 2015; 29(1):142-5. PubMed ID: 25456820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.
    O'Connor PJ; Gray RJ; Maciosek MV; Fillbrandt KM; DeFor TA; Alexander CM; Weiss TW; Teutsch SM
    Prev Chronic Dis; 2005 Jul; 2(3):A05. PubMed ID: 15963307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.